Loading search results
retroESGO ov1
Assessment of the Prognostic Impact of the Published European Society of Gynecologic Oncology Quality Indicators for Advanced Ovarian Cancer Surgery
Sponsor study identifier
observational
11,383
1 country
1
Study Start
April 26, 2023
Actual (reported)Primary Completion
December 20, 2024
Actual (reported)Study Completion
December 20, 2024
Actual (reported)This study, organized by the European Society of Gynaecological Oncology (ESGO), evaluates the clinical impact of adherence to ten ESGO-established quality indicators (QIs) in advanced ovarian cancer surgery. These indicators are benchmarks for high-quality surgical care, addressing aspects such as surgical completeness, multidisciplinary management, documentation, and perioperative care. The study seeks to determine how adherence to these QIs influences progression-free survival and overall survival among patients with advanced ovarian cancer. Conducted as a retrospective, international, multicenter cohort study, this research involves ESGO-accredited centers and includes data from patients treated over three years (2020-2022). The study examines two cohorts: (1) all patients newly diagnosed with FIGO stage III or IV ovarian cancer, regardless of whether surgery was part of their initial treatment, and (2) recurrent ovarian cancer patients undergoing secondary or tertiary cytoreductive surgeries. By including all consecutive cases, the study minimizes selection bias and ensures robust, real-world insights. The primary objective is to assess the association between adherence to QIs and progression-free survival. Secondary objectives include evaluating the relationship between QIs and overall survival, analyzing adherence rates to individual and collective QIs, and examining the influence of ESGO accreditation status on outcomes. Participating centers will submit pseudonymized patient data via a secure REDCap database, ensuring compliance with GDPR and other data protection regulations. This research aims to validate ESGO's QIs as effective tools for enhancing surgical outcomes and promoting best practices in gynecological oncology. Findings will support the refinement of institutional accreditation criteria, guide health policies on care centralization, and improve treatment strategies for advanced ovarian cancer patients. Ultimately, the study is expected to contribute to improved survival outcomes and establish a stronger evidence base for quality-focused surgical care in gynecological oncology.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
December 20, 2024
Actual (reported)Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
April 26, 2023
Actual (reported)December 20, 2024
Actual (reported)December 20, 2024
Actual (reported)January 21, 2026
Actual (reported)May 5, 2026
Actual (reported)Progression-Free Survival (PFS)
Time from initial treatment (e.g., surgery or chemotherapy) to disease progression, recurrence, or death from any cause, whichever occurs first. Measurement Method: Data collected from patient records, including imaging reports, clinical evaluations, and follow-up documentation.
Assessed over the study period (2020-2022) with a minimum follow-up of 20 months.
Overall Survival (OS)
From start of treatment until death from any cause, assessed up to 5 years (data cut-off December 2024).
Adherence to ESGO Quality Indicators
During the study period (2020-2022).
Participants with FIGO stage III or IV ovarian cancer who were newly diagnosed and managed at ESGO-accredited centers during the study period (2020-2022). This cohort includes patients irrespective of whether they underwent cytoreductive surgery during their primary treatment.
Participants with recurrent ovarian cancer who underwent secondary or tertiary cytoreductive surgery at ESGO-accredited centers during the study period (2020-2022). This cohort focuses on evaluating surgical and clinical outcomes in cases of disease recurrence.
Participants underwent preoperative assessments to determine the extent of disease, eligibility for cytoreductive surgery, and overall fitness for treatment. These evaluations typically included imaging studies, laboratory tests, and multidisciplinary tumorboards at ESGO-accredited centers.
Participants are individuals treated for advanced or recurrent ovarian cancer at ESGO-accredited centers across multiple countries. These centers include institutions with standard accreditation and centers of excellence, representing a diverse geographical and clinical practice setting. The study population reflects patients managed within routine clinical care during the period 2020-2022.
European Society of Gynaecological Oncology Aisbl
Brussels, 1200, Belgium
Wright JD, Chen L, Hou JY, Burke WM, Tergas AI, Ananth CV, Neugut AI, Hershman DL. Association of Hospital Volume and Quality of Care With Survival for Ovarian Cancer. Obstet Gynecol. 2017 Sep;130(3):545-553. doi: 10.1097/AOG.0000000000002164.
Querleu D, Planchamp F, Chiva L, Fotopoulou C, Barton D, Cibula D, Aletti G, Carinelli S, Creutzberg C, Davidson B, Harter P, Lundvall L, Marth C, Morice P, Rafii A, Ray-Coquard I, Rockall A, Sessa C, van der Zee A, Vergote I, du Bois A. European Society of Gynaecologic Oncology Quality Indicators for Advanced Ovarian Cancer Surgery. Int J Gynecol Cancer. 2016 Sep;26(7):1354-63. doi: 10.1097/IGC.0000000000000767.
Nicole Concin
Medical University of Vienna
11,383 participants (actual enrollment reported by the registry).
First Submitted
January 21, 2026
First Posted
May 5, 2026
Study Start
April 26, 2023
Actual (reported)Rate of Complete Cytoreduction
Assessed during the surgical intervention period (2020-2022).
Postoperative Complication Rates
Assessed within 30 days post-surgery.
Impact of Accreditation Status on Outcomes
From start of treatment until death from any cause, assessed up to 5 years (data cut-off December 2024).
Surgical Complexity Score
At time of surgery, for surgeries performed during the enrollment period (January 2020 - December 2022).
Multidisciplinary Team Participation
Preoperative, for cases treated during the enrollment period (January 2020 - December 2022).
Surgical procedures aimed at achieving maximal tumor reduction, often targeting complete macroscopic resection (no visible residual disease). Cytoreductive surgery was performed on eligible patients as part of routine care for advanced or recurrent ovarian cancer.
Comprehensive perioperative care provided to optimize surgical outcomes and manage complications. This included pain management, critical care support, and postoperative monitoring to ensure patient safety and recovery.
Participants received chemotherapy regimens tailored to their clinical condition, either as neoadjuvant treatment (before surgery), adjuvant treatment (after surgery), or as part of palliative care. Chemotherapy was administered per routine protocols at ESGO-accredited centers.
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
Contact the study team to confirm eligibility.
Palmqvist C, Staf C, Mateoiu C, Johansson M, Albertsson P, Dahm-Kahler P. Increased disease-free and relative survival in advanced ovarian cancer after centralized primary treatment. Gynecol Oncol. 2020 Nov;159(2):409-417. doi: 10.1016/j.ygyno.2020.09.004. Epub 2020 Sep 15.
Marth C, Abreu MH, Andersen KK, Aro KM, de Lurdes Batarda M, Boll D, Ekmann-Gade AW, Haltia UM, Hansen J, Haug AJ, Hogdall C, Korach J, Lassus H, Lindemann K, Van Nieuwenhuysen E, Ottevanger PB, Polterauer S, Schnack TH. Real-life data on treatment and outcomes in advanced ovarian cancer: An observational, multinational cohort study (RESPONSE trial). Cancer. 2022 Aug 15;128(16):3080-3089. doi: 10.1002/cncr.34350. Epub 2022 Jun 17.
Gac MM, Loaec C, Silve J, Vaucel E, Augereau P, Wernert R, Bourgin C, Aireau X, Lortholary A, Descamps P, Priou F, Deblaye P, Bourgeois H, Delecroix V, Empereur F, Campion L, Classe JM. Quality of advanced ovarian cancer surgery: A French assessment of ESGO quality indicators. Eur J Surg Oncol. 2021 Feb;47(2):360-366. doi: 10.1016/j.ejso.2020.08.003. Epub 2020 Aug 11.
Fotopoulou C, Concin N, Planchamp F, Morice P, Vergote I, du Bois A, Querleu D. Quality indicators for advanced ovarian cancer surgery from the European Society of Gynaecological Oncology (ESGO): 2020 update. Int J Gynecol Cancer. 2020 Apr;30(4):436-440. doi: 10.1136/ijgc-2020-001248. Epub 2020 Feb 20. No abstract available.
Bristow RE, Zahurak ML, Diaz-Montes TP, Giuntoli RL, Armstrong DK. Impact of surgeon and hospital ovarian cancer surgical case volume on in-hospital mortality and related short-term outcomes. Gynecol Oncol. 2009 Dec;115(3):334-8. doi: 10.1016/j.ygyno.2009.08.025. Epub 2009 Sep 18.
Alejandra M, Gertych W, Pomel C, Ferron G, Lusque A, Angeles MA, Lambaudie E, Rouzier R, Bakrin N, Golfier F, Glehen O, Canis M, Bourdel N, Pouget N, Colombo PE, Guyon F, Meurette J, Querleu D. Adherence to French and ESGO Quality Indicators in Ovarian Cancer Surgery: An Ad-Hoc Analysis from the Prospective Multicentric CURSOC Study. Cancers (Basel). 2021 Mar 30;13(7):1593. doi: 10.3390/cancers13071593.
Primary Completion
December 20, 2024
Actual (reported)Study Completion
December 20, 2024
Actual (reported)Last Updated
May 5, 2026
Record last verified: 2026-04
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: